MACSF

COMMUNIQUÉS West-GlobeNewswire

MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
22/02/2024
Topline data expected in second half of 2024 THIO-101 will be the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment CHICAGO, IL, Feb. 22, 2024 (GLOBE [...]
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts
22/02/2024
Five clinical trials across three prioritized immuno-oncology platforms with encouraging safety and efficacy signals Encouraging early results from the VAXINIA (CF33) oncolytic virus trial, including one complete [...]
Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment
22/02/2024
OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Intrommune Therapeutics [...]
Team Primary Care Summit brings together primary care leaders in Canada
22/02/2024
The Foundation for Advancing Family Medicine holds a two-day summit, gathering health care experts to enhance primary care training OTTAWA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Today, the Foundation for Advancing Family [...]
Le sommet d’Équipe de soins primaires réunit les chefs de file des soins primaires au Canada
22/02/2024
La Fondation pour l’avancement de la médecine familiale organise un sommet de deux jours qui rassemble des experts de la santé afin d’améliorer la formation en soins primaires OTTAWA, 22 févr. 2024 (GLOBE NEWSWIRE) -- [...]
USOSM Partner Practices Earn “World-Class” Net Promoter Scores Year-After-Year
22/02/2024
IRVING, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Once again, U.S. Oral Surgery Management (USOSM) surgeon partners have achieved world-class Net Promoter Score™ (NPS) status, earning an overall NPS of 86 for 2023. NPS [...]
Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023
22/02/2024
FORT WORTH, TX, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused [...]
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
22/02/2024
PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into a definitive agreement for [...]
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
22/02/2024
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic [...]
Simple Celebrates Women-Led Science Team by Spotlighting Unique Careers for Women in STEM
22/02/2024
The nutrition and wellness company highlights the women leading the company's science and debuts a giveaway for new members LIMASSOL, Cyprus, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Simple , the nutrition and wellness app [...]
PharmAla named an Intellectual Property Ontario Client
22/02/2024
IPON to grant PharmAla an initial grant of $35,000, with a further total grant of $100,000 available in subsequent funding calls VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings [...]
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
22/02/2024
SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
Gracell Biotechnologies Acquisition Completed
22/02/2024
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical company developing [...]
SOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care Conference
22/02/2024
BOSTON and ROLLE, Switzerland, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Co-founder and Chief Executive [...]
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
22/02/2024
-In vivo data supports BAER-101’s unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy- MIAMI, Feb. 22, 2024 (GLOBE [...]
Cerevance to Participate at the TD Cowen 44th Annual Health Care Conference
22/02/2024
BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced participation at the upcoming TD Cowen 44 th [...]
AssureCare Revolutionizes Pharmacist Credentialing with Groundbreaking Solution
22/02/2024
AssureCare’s AssureRx platform enables pharmacies to navigate the complexities of pharmacist credentialing with a comprehensive, seamless solution CINCINNATI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- AssureCare, a leading [...]
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
22/02/2024
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, [...]
Ashvattha Therapeutics Announces First Patient Enrolled in Expanded Phase 1/2 Study of Imaging Agent 18F-OP-801 in Additional Neurological Indications
22/02/2024
The study will evaluate the safety, tolerability, and ability of 18 F-OP-801 to cross the blood-brain barrier and selectively target neuroinflammation in individuals with amyotrophic lateral sclerosis, Alzheimer’s [...]

Pages